Cellceutix' Kevetrin activates 'Guardian Angel p53' in fight against leukemia
Massachusetts, USA-based Cellceutix (OTCQB: CTIX) says that its flagship cancer compound, Kevetrin, has demonstrated potent anti-tumor activity in the treatment of leukemia cells in a hematopoietic xenograft tumor model. The activity, once again, is attributed to the reactivation of p53, the "Guardian Angel" protein, which Cellceutix previously announced as a major breakthrough in cancer research.
The data were presented to Cellceutix Scientific Advisor, Emil Frei III, who is Physician-in-Chief emeritus at Harvard University's Dana-Farber Cancer Institute and Distinguished Professor of Medicine at Harvard Medical School. After reviewing the most recent data on Kevetrin's method of action regarding leukemia, Dr Frei commented: "The p53 mechanism of Kevetrin as a possible new therapy for leukemia is very exciting and holds significant promise.”
IND filing set for May
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze